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Interleukin-23 (IL-23) and CD4+ T helper 17 (Th17)
cells are thought to be critical in psoriasis pathogen-
esis. Here, we report that IL-23 predominantly stimu-
lated dermal gd T cells to produce IL-17 that led to
disease progression. Dermal gd T cells constitutively
expressed the IL-23 receptor (IL-23R) and transcrip-
tional factor RORgt. IL-17 production from dermal gd
T cells was independent of ab T cells. The epidermal
hyperplasia and inflammation induced by IL-23 were
significantly decreased in T cell receptor d-deficient
(Tcrd/) and IL-17 receptor-deficient (Il17ra/)
mice but occurred normally in Tcra/ mice. Imiqui-
mod-induced skin pathology was also significantly
decreased in Tcrd/ mice. Perhaps further pro-
moting disease progression, IL-23 stimulated dermal
gd T cell expansion. In psoriasis patients, gd T cells
were greatly increased in affected skin and produced
large amounts of IL-17. Thus, IL-23-responsive
dermal gd T cells are the major IL-17 producers in
the skin and may represent a novel target for the
treatment of psoriasis.
INTRODUCTION
Psoriasis is one of the most common immune-mediated chronic
inflammatory skin disorders characterized by hyperproliferative
keratinocytes and massive infiltration of leukocytes (Scho¨n and
Boehncke, 2005). Although the pathogenesis of psoriasis is not
fully understood, there is growing evidence that the interleukin-
23 (IL-23)-T helper 17 (Th17) cell axis and Th17 cell-related
cytokines play critical roles in disease development (Clark,
2010; Di Cesare et al., 2009; Zaba et al., 2009).
Psoriatic skin lesions are reported to have increased gene and
protein expression of IL-23, IL-21, IL-22, and IL-17 (Boniface
et al., 2007; Caruso et al., 2009; Johansen et al., 2009; Lee
et al., 2004). IL-23-induced changes in mouse skin share many
characteristics with human psoriasis, including erythematosus,
hyperplasia of the epidermis (acanthosis), parakeratosis, and
leukocyte infiltration (Chan et al., 2006). The dermal inflammation
and acanthosis induced by IL-23 are thought to be mediated by596 Immunity 35, 596–610, October 28, 2011 ª2011 Elsevier Inc.a Th17 cell cytokine, IL-22 (Zheng et al., 2007), and the chemo-
kine receptor CCR6 expression is required as well (Hedrick et al.,
2009). The importance of IL-23 is further demonstrated by the
therapeutic efficacy of human mAb against the subunit of p40
of IL-12 and IL-23 in the treatment of psoriasis (Griffiths et al.,
2010; Krueger et al., 2007). IL-23-induced skin inflammation
has primarily been linked to the function of Th17 cells and related
cytokines (Di Cesare et al., 2009; Harper et al., 2009; Steinman,
2010; Zaba et al., 2009). Therefore, IL-23 and Th17 cells may be
key mediators of disease pathogenesis (Blauvelt, 2008). One
caveat of these studies is that although elevated IL-17 and
IL-22 production is observed in psoriatic skin (Harper et al.,
2009; Lowes et al., 2008; Wilson et al., 2007; Zaba et al., 2007),
it is not presently knownwhether these cytokines, e.g., IL-17, are
directly secreted by Th17 cells. Thus, the primary IL-17-pro-
ducing cells responsive to IL-23 stimulation in skin remain to
be determined. Furthermore, the pathogenic role of these cells
that induce skin inflammation and acanthosis in psoriasis needs
to be established. These issues are significant because psoriasis
is currently considered to be a CD4+ Th17 cell-mediated disease
(Di Cesare et al., 2009; Lowes et al., 2008; Steinman, 2010).
Murine epidermis contains large numbers of gd T cells (Hayday
and Tigelaar, 2003). These gd T cells have a marked dendritic
morphology and have been named dendritic epidermal T cells
(DETCs) (Havran and Jameson, 2010). In addition, gd T cells
exist in both human and murine dermis. In this study, we found
that innate dermal gd T cells—but not epidermal gd T cells or
dermal gd T cells—were the major IL-17-producing cells in
the skin after IL-23 stimulation. Deficiency of gd T cells or IL-17
receptor significantly decreased IL-23-induced epidermal thick-
ness and neutrophil infiltration. This was also the case in the
imiquimod (IMQ)-induced psoriasis-like model. Furthermore,
IL-17-secreting gd T cells were present in high frequency in
human psoriatic skin lesions. These observations support the
idea that IL-17-producing dermal gd T cells are a key component
in the pathogenesis of psoriasis.RESULTS
IL-23 Is Mainly Produced by Dermal Dendritic Cells
and Macrophages, which Is Critical for IL-17 Production
in the Skin
IL-23 has been clearly linked to the pathogenesis of psoriasis
(Chan et al., 2006). Previous studies demonstrate that transcripts
Figure 1. DCs and Mf Are the Major Cellular Sources of IL-23 in Psoriatic Skin
(A) Frozen skin sections from patients with psoriatic lesions (scale bars represent 25 mm) and healthy controls (scale bars represent 100 mm) were stained with
anti-human IL-23p19 (green), anti-human CD11c (red), or anti-human CD68 (red) and DAPI (blue) for immunofluorescent staining.
(B) Representative H&E-stained sections of the back skin of C57BL/6 WT mice treated for 3 consecutive days with control cream or IMQ are shown (scale bars
represent 100 mm). IL-17 and IL-23p19 mRNA concentrations were measured by qPCR. Data are shown as mean ± SEM.
(C) Frozen sections from 3 days of IMQ-treated mouse back skin were costained with anti-mouse IL-23p19 (green) and anti-mouse CD11c (red) or with
anti-mouse F4/80 (red) and DAPI (blue) for immunofluorescent staining. Scale bars represent 25 mm.
(D and E) Whole mouse skin cells, skin cells devoid of DCs and Mf, or purified skin DCs and Mf were stimulated with IMQ for 24 hr or 3 hr and IL-23p19 (D) and
IL-17 (E) mRNA concentrations were measured by qPCR. Data are shown as mean ± SEM.
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Dermal gd T Cells in Skin Inflammationencoding IL-23p19 and IL-23p40 are increased during human
psoriasis (Lee et al., 2004). To dissect the cellular source of
IL-23, skin tissues from healthy individuals and patients withpsoriasis were analyzed by immunofluorescent staining. We
found that IL-23p19 protein was colocalized with CD11c+
dendritic cells (DCs) and CD68+ macrophages (Mf) (Figure 1A)Immunity 35, 596–610, October 28, 2011 ª2011 Elsevier Inc. 597
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Dermal gd T Cells in Skin Inflammationin the lesional dermis. IL-23p19 protein was not present in skin
from healthy donors. In addition, DCs and Mf were increased
in psoriatic lesions. We further established an IMQ-induced
psoriasis-like model to examine IL-23-secreting cells in mice
(van der Fits et al., 2009). IMQ is a Toll-like receptor-7 and -8
(TLR7 and 8) ligand and can exacerbate psoriasis development
in patients (Gilliet et al., 2004; Rajan and Langtry, 2006). IMQ
topical treatment induced typical psoriasis-like manifestations
including epidermal thickness, erythema, and inflammation (Fig-
ure 1B). IL-23 and IL-17 mRNAs were increased in the lesional
skin. Analysis of lesional skin sections by immunofluorescent
staining with IL-23p19 mAb demonstrated that IL-23p19 protein
was colocalized with DCs and Mf distributed throughout the
dermis, suggesting that DCs and Mf are the predominant cells
secreting IL-23 (Figure 1C).
We further usedwhole skin cells or skin cells devoid of DCs and
Mf to detect IL-23p19 transcripts in vitro upon IMQ stimulation.
The IL-23p19 mRNA was increased in total skin cells after IMQ
stimulation. However, it was decreased when skin cells were
devoid of DCs andMf (Figure 1D). IMQ stimulated high amounts
of IL-23p19 mRNA on skin DCs and Mf. Finally, we examined
whether IL-23 secreted by DCs and Mf was responsible for
skin IL-17 production. Whole skin cells stimulated with IMQ
produced high amount of IL-17 mRNA whereas skin cells devoid
of DCs and Mf did not transcribe appreciable amounts of IL-17
mRNA (Figure 1E). These data suggest that IL-23 secreted by
skin DCs and Mf is essential for IL-17 production in the skin.
Dermal gd T Cells Are the Major Source of IL-17 upon
IL-23 Stimulation in the Skin
To detect IL-17-producing cells in the skin, single-cell suspen-
sions were prepared from both murine epidermis and dermis.
The gating strategy is shown in Figure S1 (available online).
Epidermal T cells were exclusively gd T cells with high intensity
of CD3 and T cell receptor gd (gdTCR) staining and did not
produce any appreciable IL-17 in response to IL-23 stimulation
(Figure 2A). In contrast, dermal T cells were approximately
50% gd and 50% ab T cells with intermediate intensity of CD3
and gdTCR staining, and IL-17 was mainly secreted by the
dermal gd T cells upon IL-23 stimulation (Figure 2A). Dermal gd
T cells constituted approximately 90% of IL-17-producing cells
(Figure 2B). Minimal IL-17 production was observed from dermal
gdTCR-negative T cells (Figure 2C). Because skin cell prepara-
tions contain many other cell subsets, dermal CD3+TCRgd+
T cells and CD3+TCRgd T cells were sorted and stimulated
with IL-23 alone or in combination with IL-1b. As depicted in
Figure 2D, IL-23 or IL-1b alone could not stimulate dermal gd
T cells for IL-17 production. However, the combination of IL-23
and IL-1b stimulated dermal gd T cells to produce large amounts
of IL-17. Dermal gdTCR T cells also secreted detectable IL-17
upon IL-23 and IL-1b stimulation but the concentration was
10-fold lower compared to dermal gd T cells. The requirement
of IL-1b for IL-23-induced skin dermal gd T cell IL-17 production
was further confirmed by using neutralizing IL-1b mAb and IL-1
receptor type I-deficient (Il1r1/) mouse skin cells (Figure 2E).
Collectively, these data suggest that, in mice, dermal gd T cells
are the major IL-17-producing cells in the skin in response to
IL-23 stimulation and that the production of IL-17 by dermal gd
T cells requires endogenous IL-1b.598 Immunity 35, 596–610, October 28, 2011 ª2011 Elsevier Inc.IL-17-Producing Dermal gd T Cells Are Phenotypically
Unique
gd T cells accounted for 0.5%–1% of total dermal cells in naive
C57BL/6 mouse skin. To determine whether dermal gd T cells
used a unique gdTCR, we measured the TCR Vg usage by using
a panel of antibodies specific for various Vg TCR segments
including Vg1, Vg4, Vg5, Vg6, and Vg7 (Heilig and Tonegawa,
1986). As depicted in Figure 3A, a fraction of dermal gd T cells
expressed Vg4 whereas epidermal gd T cells expressed exclu-
sively Vg5 and partly cross-reacted with Vg6 antibody (Roark
et al., 2004). Reverse transcriptase-polymerase chain reaction
(RT-PCR) analysis revealed that dermal gd T cells could also
use a Vg2 gene segment (Figure S2C). Consistent with previous
results (Born et al., 2010), splenic gd T cells preferentially
expressed Vg1 and Vg4 and both were capable of producing
IL-17 (Figure S2B). In addition, approximately 50% of IL-17-pro-
ducing dermal gd T cells expressed Vg4 (Figure 3B). To further
delineate the role of Vg4 T cells in skin IL-17 production, mice
were injected with Vg4-depleting mAb. We found that IL-17
production from dermal gd T cells was significantly decreased
after Vg4 T cell depletion (Figure 3C).
The chemokine receptor CCR6 and transcriptional factor
RORgt are associated with the development and recruitment
of CD4+ Th17 cells and are also expressed on splenic gd
T cells (Martin et al., 2009). We found that dermal gd T cells,
but not epidermal gd T cells, constitutively expressed CCR6
and RORgt (Figures 3D and 3E). We also used real-time PCR
to further explore their chemokine receptor mRNA expression
profiles and IL-23R expression. As shown in Figure 3F, dermal
gd T cells expressed constitutively IL-23R, along with the che-
mokine receptors CCR1, CCR2, CCR4, CCR5, CCR6, CXCR3,
and CXCR4. These findings suggest that dermal gd T cells
display a unique TCR Vg usage and chemokine receptor profile
with IL-17-producing capability.
CD27 has recently been defined as a critical molecule that
differentiates interferon-g (IFN-g)-producing versus IL-17-
producing gd T cells (Ribot et al., 2009; Wakita et al., 2010).
Skin dermal and epidermal gd T cells were exclusively CD27
and did not produce any appreciable IFN-g (Figure S2D). In con-
trast, lymph node (LN) gd T cells have both CD27+ and CD27
populations. Consistent with previous findings, only the CD27+
population produced IFN-g (Figure S2D). To further investigate
whether dermal gd T cells produce other cytokines such as
IL-22 and tumor necrosis factor-a (TNF-a), gd T cells from skin
or LNs were stimulated. Skin dermal gd T cells produced large
amounts of IL-17 and intermediate amounts of TNF-a and
IL-22 (Figure S2E) whereas LN gd T cells produced IL-17,
IL-22, TNF-a, and IFN-g. Thus, dermal gd T cells appear to be
developmentally skewed toward IL-17-producing cells.
gd T Cells Are Required for IL-23- and IMQ-Induced
Skin Inflammation and Acanthosis
Having found that dermal gd T cells are the major IL-17-
producing cells upon IL-23 stimulation, we tested whether these
cells might be involved in a model of IL-23-induced skin inflam-
mation, which shares some features with human psoriasis. We
used wild-type (WT) and Tcrd/ mice to first assess IL-17 pro-
duction from skin cells. Dermal T cells from WT mice produced
significant amounts of IL-17 and dermal gd T cells were the
Figure 2. Dermal gd T Cells Are the Predominant IL-17 Producers upon IL-23 Stimulation in the Skin
Intracellular IL-17 production assessed by flow cytometry on epidermal and dermal cell suspensions from C57BL/6 WT mice that were stimulated with IL-23 for
18 hr.
(A) Cells were gated on CD3+ T cells.
(B) Dermal IL-17-producing cells were gated and calculated for gdTCR expression.
(C) Percentages of IL-17-producing cells in dermal CD3+gdTCR+ cells, dermal CD3+gdTCR cells, and epidermal CD3+gdTCR+ cells were analyzed from
12 independent experiments. Data are shown as mean ± SEM. ***p < 0.001 (unpaired Student’s t test).
(D) Dermal CD3+gdTCR+ cells and CD3+gdTCR cells were sorted and then stimulated with IL-23 in the presence or absence of IL-1b for 2 days. IL-17 production
was measured by ELISA.
(E) Skin cells from WT or Il1r1/ mice were stimulated with IL-23, IL-1b, or IL-23 plus IL-1b mAb or isotype control mAb. Intracellular IL-17 concentration was
assessed by flow cytometry. Cells were gated on CD3+ T cells.
See also Figure S1.
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Figure 3. Phenotypic Analysis of Dermal gd T Cells versus Epidermal gd T Cells
(A) Epidermal and dermal cell suspensions were stained with a panel of different Vg TCR antibodies (Vg1, Vg4, Vg5, Vg6, and Vg7) and analyzed by flow
cytometry. Flow plots gated on CD3+ cells are representative of two independent experiments with similar results.
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Dermal gd T Cells in Skin Inflammationpredominant IL-17 producers. In contrast, dermal T cells from
Tcrd/ mice secreted minimal IL-17 (Figure 4A). Previous
studies demonstrated that autoreactive T cell IL-17 production
requires interaction of ab and gd T cells (Cui et al., 2009).
However, Tcra/ skin cells produced similar amount of IL-17
(Figure 4A), predominantly from dermal gd T cells, suggesting
that the IL-17 production from dermal gd T cells is independent
of ab T cells.
IL-23-induced changes in mouse skin share many character-
istics with human psoriasis (Chan et al., 2006). In agreement
with a previous report (Chan et al., 2006), WTmice injected intra-
dermally with IL-23 developed epidermal thickening and
massive neutrophil infiltration (Figure 4B). These changes were
significantly decreased in Tcrd/mice but were not significantly
altered in Tcra/ mice (Figure 4B). We used real-time PCR on
skin tissues to assess the effect of IL-23 on mRNA expression
of IL-17, IL-22, TNF-a, IL-6, matrix metalloprotease-9 (MMP-9),
and IFN-g. IL-17 and IL-22 mRNAs were significantly increased
in WT mice receiving IL-23 injection and both were significantly
decreased in Tcrd/ mice compared to WT mice (Figure 4C).
In Tcra/ mice, IL-17 mRNA was similar to that in WT mice
but IL-22 mRNA was significantly lower than that in WT mice
(Figure 4C). We also examined IL-17 production in skin draining
LNs (DLNs) and spleen from thesemice to determine IL-23 effect
on local and systemic IL-17 production. In skin DLNs, the fre-
quency of IL-17-producing cells was not significantly changed
in mice lacking ab or gd T cells upon phorobol myristate acetate
(PMA) plus ionomycin stimulation (Figure 4D). Both gd and ab
T cells produced IL-17. However, upon IL-23 stimulation,
IL-17-producing cells in Tcrd/ mice were significantly lower
as compared to those in WT or Tcra/ mice and IL-17 was
predominantly produced by gd T cells (Figures 4D). Tcra/
mice in fact had the highest frequency of IL-17-producing cells.
Splenic IL-17-producing cells were not significantly altered in
thesemice (Figures 4E). Together, these in vivo data corroborate
our in vitro observations that IL-23 preferentially promotes IL-17
production from gd T cells. These data further suggest that gd
T cells are required for IL-23-induced skin inflammation and
acanthosis.
Because IMQ-induced psoriasis-like murine model is also
mediated by the IL-23-IL-17 axis as described previously (van
der Fits et al., 2009) as well as demonstrated in our study (Fig-
ure 1B), we examined whether dermal gd T cells are also respon-
sible for skin IL-17 production. Dermal gd T cells spontaneously
secreted a large amount of IL-17 in IMQ-treated skin cells (Fig-
ure S3A). In addition, gd T cells were increased in both skin
and LNs from IMQ-treated mice and secreted large amount of
IL-17. Consistent with the IL-23-injected psoriasis model, the
frequency of splenic gd T cells and IL-17 production from gd
T cells were not altered. To further assess the role of gd T cells(B) Dermal cell suspensions were stimulated with IL-23 for 18 hr and analyzed for
TCR antibodies. Flow plots gated on CD3+ cells are representative of two indep
(C) Dermal cells from C57BL/6WTmice receiving mouse Vg4mAb or isotype cont
was determined by flow cytometry. Percentages of IL-17+CD3+gdTCR+ cells we
SEM; *p < 0.05 (unpaired Student’s t test).
(D and E) CCR6 (D) and RORgt (E) expression on epidermal and dermal gd T cel
(F) Expression of chemokine receptors and IL-23RmRNAmeasured by qPCR in FA
indicated genes normalized for b-MG mRNA versus the epidermal gd T cells.
See also Figure S2.and ab T cells in the IMQ-induced mouse model of psoriasis,
WT, Tcra/, and Tcrd/ mice were treated with or without
IMQ cream. WT mice treated with IMQ had significantly in-
creased epidermal hyperplasia and massive neutrophil infiltra-
tion (Figures S3B and S3C). However, the epidermal thickening
and neutrophil infiltration induced by IMQ were significantly
decreased in Tcrd/ mice. In contrast to IL-23-induced skin
inflammation, IMQ-induced epidermal hyperplasia was also sig-
nificantly decreased in Tcra/ mice (Figure S3B). However,
neutrophil infiltration induced by IMQ was not significantly
different in Tcra/ mice (Figure S3C). Furthermore, real-time
PCR analysis revealed that IL-17 mRNA was increased upon
IMQ treatment. However, the IL-17 mRNA in Tcrd/ mice was
lower than that in WT mice and Tcra/ mice (data not shown).
Similarly, IL-22 mRNA was increased after IMQ treatment.
There was no difference among WT, Tcra/, and Tcrd/
mice (data not shown). These data suggest that dermal gd
T cells are also the major IL-17-producing cells that are critical
in an IMQ-induced psoriasis-like model.
IL-17R Expression Is Necessary for IL-23-Induced
Epidermal Hyperplasia and Inflammation
The IL-17 cytokine family includes six members, IL-17A to F.
IL-17A and IL-17F mediate inflammatory activities via the
IL-17R complex, comprised of the IL-17RA and IL-17RC
subunits (Gaffen, 2009). The IL-17R is expressed ubiquitously
in hematopoietic tissues (Yao et al., 1995) as well as in psoriatic
lesions (Johansen et al., 2009). As shown in Figure 5A, the epi-
dermal hyperplasia induced by IL-23 was markedly decreased
in Il17ra/ mice compared to WT mice. Neutrophil infiltration
was also significantly decreased in these mice. Real-time PCR
indicated that mRNA concentrations of IL-17 and IL-22 were
increased upon IL-23 treatment in both WT and Il17ra/ mice.
The mRNAs of TNF-a, MMP-9, and IFN-g remained unchanged
but IL-6 mRNA amount was significantly decreased in Il17ra/
mice (Figure 5B). This suggests that downstream IL-17R
signaling is critical in IL-23-induced epidermal hyperplasia.
IL-23 but Not Pathogen Products Stimulates In Vitro
Expansion of Dermal gd T Cells
Microbial infection is thought to be important in the initiation of
psoriasis (Gudjonsson et al., 2003; Cai et al., 2009). Previous
studies demonstrated that the TLR2 agonist Pam3CSK4, but
not IL-23, stimulates splenic gd T cell expansion in vitro (Rey-
nolds et al., 2010). We therefore stimulated skin cells with
different pathogen products or IL-23. Pam3CSK4 and other
pathogen products alone did not stimulate dermal gd T cell
proliferation (Figure 6A and data not shown). However, IL-23
alone was found to be sufficient for driving dermal gd T cell prolif-
eration, but not for dermal gd T cells or epidermal gd T cellsintracellular IL-17 expression by flow cytometry after staining with different Vg
endent experiments.
rol mAb for 3 days were stimulated with IL-23 and intracellular IL-17 expression
re analyzed from three independent experiments. Data are shown as mean ±
ls were determined by flow cytometry.
CS-sorted epidermal or dermal gd T cells. The figure shows fold changes of the
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Figure 4. gd T Cells Are Critical in IL-23-Induced Skin Inflammation and Acanthosis
(A) Dermal cell suspensions from C57BL/6 WT, Tcrd/, and Tcra/ mice were stimulated with IL-23 and analyzed for intracellular IL-17 expression by flow
cytometry. Flow plots gated on CD3+ cells are representative of two independent experiments. Data are shown as mean ± SEM.
(B) C57BL/6 WT (n = 12), Tcrd/ (n = 12), and Tcra/ (n = 8) mice received daily intradermal injections with IL-23 or vehicle control for 4 days. Representative
H&E-stained sections and frozen sections stained with Gr-1 are shown. Epidermal thickness and Gr-1 infiltration were measured at day 4. Scale bars represent
100 mm. Data are combined from two independent experiments. *p < 0.05, ***p < 0.001; n.s., not significant (unpaired Student’s t test).
Immunity
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Figure 5. IL-17R Expression Is Essential for IL-23-Induced Epidermal Hyperplasia
C57BL/6 WT (n = 5) and Il17ra/ (n = 5) mice received daily intradermal injections with IL-23 or vehicle control for 4 days.
(A) Representative H&E-stained sections and frozen sections stained with Gr-1 are shown. Epidermal thickness and Gr-1 infiltration were measured at day 4.
Scale bars represent 100 mm. Data are shown as mean ± SEM.
(B) IL-17, IL-22, IL-6, TNF-a, MMP-9, and IFN-g mRNA concentrations were measured by qPCR. The figure shows fold changes normalized for b-MG mRNA
versus control skin from WT mice. Data are shown as mean ± SEM. **p < 0.01, ***p < 0.001 (unpaired Student’s t test).
Immunity
Dermal gd T Cells in Skin Inflammation(Figure 6A). In contrast, Pam3CSK4, but not IL-23, stimulated
splenic gd T cell proliferation (Figure S4), consistent with a pre-
vious report (Reynolds et al., 2010). These data suggest that
IL-23 is essential for both maintaining dermal gd T cell homeo-
stasis and regulating its differentiation program.(C) IL-17, IL-22, IL-6, TNF-a, MMP-9, and IFN-g mRNA concentrations were me
versus IL-23-injected skin from Tcrd/ mice. Data are representative of two ind
(D and E) Skin-draining LN cells (D) or splenocytes (E) from IL-23-treated mic
expression was determined by flow cytometry. Upper panels are representative d
gated on the CD3+ T cells. *p < 0.05, **p < 0.01 (unpaired Student’s t test).
See also Figure S3.We next examined the effect of these pathogen products on
dermal gd T cell IL-17 production. TLR agonists Pam3CSK4
(TLR2), Gardiquimod (TLR7), and CpG (TLR9) but not lipopoly-
saccharide (LPS) (TLR4) or dectin-1 ligand curdlan (Lei-
bundGut-Landmann et al., 2007) stimulated dermal gd T cellsasured by qPCR. The figure shows fold changes normalized for b-MG mRNA
ependent experiments and shown as mean ± SEM.
e were stimulated with PMA plus ionomycin or IL-23 and intracellular IL-17
ot plots gated on the total cells. The lower panels are representative dot plots
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Figure 6. Dermal gd T Cell In Vitro Expansion and IL-17 Production Stimulated by IL-23 Combined with Specific Pathogenic Products
(A) Skin cell suspensions were labeled with CFSE and then stimulated with Pam3CSK4 or IL-23 for 3 days. Cells were harvested and stained with CD3 and gdTCR
mAbs.
(B) Skin cells were stimulated with IL-23 alone, different pathogen products (LPS, Pam3CSK4, Curdlan, Gardiquimon, or CpG), or IL-23 plus different pathogenic
products for 2 days. Intracellular IL-17 production was determined by flow cytometry. Cells were gated on CD3+ T cells.
(C) Supernatants harvested from (B) were measured for IL-17 concentration by ELISA. Data are shown as mean ± SEM.
(D) Skin cells from WT and Il1r1/ mice were stimulated with IL-23 plus different pathogen products for 2 days. Supernatants were harvested and IL-17
concentrations were determined by ELISA. Data are shown as mean ± SEM.
Data are representative of at least three independent experiments with similar results.
See also Figure S4.
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Dermal gd T Cells in Skin Inflammationto produce low amount of IL-17 as assessed by intracellular
cytokine staining (Figure 6B). Combining pathogenic products
with IL-23 did not increase the percentage of IL-17-producing
cells. However, the mean fluorescent intensity of IL-17 produc-
tion was increased. Furthermore, a synergistic effect on IL-17
production as assessed by ELISA was observed when cells
were exposed to both IL-23 and pathogen products (Figure 6C).
IL-17 production by gd T cells from the peritoneum, lungs, and
spleen requires both IL-23 and IL-1b stimulation (Duan et al.,
2010; Sutton et al., 2009). Similarly, IL-17 production from
dermal gd T cells was completely abrogated in Il1r1/mice (Fig-
ure 6D), suggesting that the IL-1R signaling pathway is essential
for pathogen product-mediated IL-17 production in skin.
Large Numbers of IL-17-Secreting gd T Cells in Human
Psoriatic Skin
We next examined dermal gd T cells in lesions from patients with
psoriasis. Unlike the case in murine skin, gd T cells do not exist in
human epidermis but approximately 4% of human dermal leuko-
cytes are CD3+gdTCR+ T cells (Ebert et al., 2006). We found that
CD3+ T cells were significantly increased in psoriatic lesions
whereas CD3+ T cells were scarce in healthy control skins (Fig-
ure 7A). In addition, the frequency of gd T cells in dermis was
significantly increased in patients with psoriasis compared to
healthy controls (Figure 7A). Confocal microscopy analysis re-
vealed that infiltration of gd T cells was readily seen in the dermis
of psoriatic skin lesions (Figure 7B). We further analyzed IL-17
production from these cells. Healthy control dermal gd T cells
produced minimal IL-17 even when these cells were stimulated
with IL-23, probably because of lower or absent endogenous
IL-1b (Kryczek et al., 2008). In contrast, approximately 15% of
gd T cells in psoriatic lesions produced IL-17 upon IL-23
stimulation (Figure 7C). Furthermore, the percentage of gd
T cells secreting IL-17 was significantly higher than that of gd
T cells secreting IL-17. Similarly, the absolute numbers of IL-17-
secreting gd T cells were significantly higher than those of IL-17-
secreting gd T cells (Figure 7C). To further compare the amount
of IL-17 production on a per cell basis, we examined the mean
fluorescent intensity (MFI) of IL-17-producing cells. However,
we did not see difference of MFI between IL-17-secreting dermal
gd T cells and gd T cells (data not shown). These data demon-
strate that dermal gd T cells in patients with psoriasis are greatly
increased and produce substantial amounts of IL-17.
DISCUSSION
Our results demonstrate that murine innate dermal gd T cells are
the major source of IL-17 upon IL-23 stimulation in skin and that
these cells constitutively express RORgt, IL-23R, CCR6, and
other chemokine receptors. Furthermore, in mice, IL-17 produc-
tion by dermal gd T cells appears to be independent of ab T cells.
Importantly, IL-23-induced skin inflammation and acanthosis are
significantly attenuated in Tcrd/ mice and Il17ra/ mice. In
addition, IMQ-induced skin inflammation and epidermal hyper-
plasia are also significantly decreased in Tcrd/ mice. In vitro,
IL-23 preferentially stimulates dermal gd T cell proliferation, sug-
gesting a possible feed-forward mechanism in the pathogenesis
of psoriasis. Finally, in both mice and humans, dermal gd T cells
are critical IL-17-producing cells in the genesis of psoriasis.A major role of IL-23 in autoimmunity is thought to be promo-
tion of Th17 cell expansion and survival (Kikly et al., 2006). A
recent study reveals that IL-23 together with IL-1b activates
splenic gd T cells to produce IL-17 (Sutton et al., 2009). Micro-
biota also regulate the production of IL-17 from gd T cells (Duan
et al., 2010). IL-23 has a central role in the pathogenesis of
psoriasis (Krueger et al., 2007; Lee et al., 2004). The cellular
sources of IL-23 in skin are mainly infiltrating DCs and mono-
cytes in the dermis (Lee et al., 2004; Wilson et al., 2007), with
keratinocytes and Langerhans cells in the epidermis (Aliahmadi
et al., 2009; Piskin et al., 2006). We found that IL-23 is mainly
secreted by skin-infiltrating DCs andMf in both human psoriatic
skin and IMQ-induced mouse psoriatic skin lesions. IL-23 not
only promoted IL-17 production by dermal gd T cells that was
irrespective of gdTCR stimuli but also drove their in vitro expan-
sion. IL-17 production by dermal gd T cells required endoge-
nous IL-1b as shown by the fact that sorted dermal gd T cells
could not secrete IL-17 upon stimulation with IL-23 alone.
However, psoriatic skin keratinocytes and infiltrating inflamma-
tory cells do secrete elevated amounts of IL-1b (Yoshinaga
et al., 1995). IL-1b treatment results in an upregulation of tight
junction (TJ) proteins occludin and ZO-1, which resembles TJ
protein alteration in early psoriasis (Kirschner et al., 2009).
Thus, skin dermal gd T cells, as well as gd T cells from spleen,
LNs, lungs, and peritoneum (Duan et al., 2010; Sutton et al.,
2009), require both IL-23 and IL-1b cytokines for IL-17
production.
The dermal IL-17-producing gd T cells share many character-
istics with other IL-17-producing cell subsets (Hedrick et al.,
2009), including constitutive expression of RORgt, CCR6, and
IL-23R. The dermal gd T cells also constitutively express a
number of chemokine receptors including CCR1, CCR2,
CCR4, CCR5, CXCR3, and CXCR4, which may be involved in
their trafficking. In addition, dermal gd T cells express lower
intensity of CD3 and gdTCR as compared to epidermal gd
T cells. It is worth noting that there is a small percentage of a
CD3hi population existing in the dermal preparations. These
CD3hi gd T dermal cells are probably contaminating epidermal
gd T cells because they express a unique Vg5 (data not shown)
gene segment, which is a hallmark of epidermal gd T cells.
However, it is also possible that these cells are bona fide dermal
residents. Compared to the previous studies indicating that gd
T cells expressing Vg1 and Vg4 gene segments are predomi-
nantly IL-17-producing gd T cells (Cui et al., 2009; Martin et al.,
2009), we found that the dominant dermal IL-17-producing gd
T cells are Vg4+ because depletion of Vg4 T cells in the skin
significantly decreased IL-17 production from dermal gd
T cells. We also found that dermal gd T cells express the Vg2
gene segment. Although dermal gd T cells share many features
with other IL-17-producing gd T cells, they bear some unique
characteristics. First, dermal gd T cells are uniformly CCR6+,
whereas gd T cells from LNs or spleen contain both CCR6+
and CCR6 populations (Martin et al., 2009). Similarly, dermal
gd T cells do not express CD27 whereas gd T cells from other
anatomical sites have both CD27+ and CD27 populations. In
addition, dermal gd T cells do not produce IFN-g whereas gd
T cells from other anatomical sites produce both IFN-g and
IL-17. This may imply that dermal gd T cells are ‘‘professional’’
IL-17-producing cells. Second, IL-23 is capable of stimulatingImmunity 35, 596–610, October 28, 2011 ª2011 Elsevier Inc. 605
Figure 7. Skin Lesions from Psoriasis Patients Display High Frequency of IL-17-Secreting gd T Cells
(A) Dermal cells from psoriatic lesions or healthy controls were analyzed for CD3 and gdTCR expression by flow cytometry. Two donors from each group (both dot
plots and contour plots) were shown. Flow plots gated on CD3+ cells are representative from 12 patients and 6 healthy controls. Percentage of CD3+gdTCR+ cells
is shown as mean ± SEM. Statistical analysis was performed by a two-tailed Mann Whitney test. **p < 0.01.
(B) Frozen sections from psoriatic lesion and healthy controls were stained with human gdTCR mAb (red), CD3 mAb (green), and DAPI (blue) for immunofluo-
rescent staining. Scale bars represent 10 mm.
(C) Dermal cell suspensions from psoriatic lesion (PS) and healthy control (NC) were stimulated with IL-23, and IL-17 expression was determined by flow
cytometry. Cells were gated on CD3+gdTCR+ or CD3+gdTCR cells. Percentage of IL-17+CD3+gdTCR+ and IL-17+CD3+gdTCR cells is shown as mean ± SEM.
Absolute numbers of IL-17-producing cells per million cells are shown from 12 patients. *p < 0.05, **p < 0.01, ***p < 0.001 (a Mann-Whitney test).
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effect on splenic gd T cell proliferation (Reynolds et al., 2010).
The pathogenic importance of gd T cell response in murine
psoriasis models is emphasized by significant decreases of
acanthosis and skin inflammation in Tcrd/ mice. In contrast,
Tcra/ mice respond to IL-23 just as do WT mice, and dermal
gd T cells from Tcra/ mice produce similar amounts of IL-17.
Consistent with in vitro data, Tcrd/ mice have lower IL-17
mRNA. Notably, IL-22 mRNA in Tcra/ mice was lower than in
WT mice, yet these mice still developed acanthosis and skin
inflammation. It is possible that the IL-22 concentration in
Tcra/ mice, although low, is sufficient to induce biological
effects. Alternatively, IL-22 may not be absolutely required for
IL-23-induced skin inflammation and acanthosis. This notion is
further supported by the observation in Il17ra/ mice in which
IL-22 mRNA was increased upon IL-23 injection but acanthosis
and skin inflammation were completely abrogated. It is worth
noting that Tcrd/ mice did show minor epidermal hyperplasia
and neutrophil infiltration compared to PBS-treated WT mice.
This may be related to the IL-23-mediated T cell-independent
inflammatory process (Buonocore et al., 2010; Hedrick et al.,
2009). In the current study, we also observed that the epidermal
hyperplasia induced by IL-23 was completely abrogated in
Il17ra/ mice despite similar IL-17 mRNA amount, whereas an
earlier report indicated that IL-23-induced acanthosis was inde-
pendent of IL-17A (Chan et al., 2006). A recent study using both
Il17a/mice and neutralizing IL-17A mAb clearly demonstrated
that IL-17A is a pathogenic cytokine in IL-23-induced skin inflam-
mation and acanthosis (Rizzo et al., 2011). In addition, an initial
phase II double-blind, randomized trial has demonstrated the
therapeutic efficacy of a fully human IL-17A mAb (AIN457) in
psoriasis treatment (Miossec et al., 2009).
We further demonstrated that dermal gd T cells secreted large
amount of IL-17 in an IMQ-induced psoriasis model. IMQ cream
topical treatment induces exacerbated psoriasis in patients with
a well-controlled psoriasis pathology (Rajan and Langtry, 2006).
Interestingly, IMQ-induced dermatitis is diminished in mice
treated with CD3 mAb or in Rag2/gc/ mice (van der Fits
et al., 2009). Although Th17 cells were marginally increased,
dermal gd T cells were increased in skin and DLNs and produced
large amounts of IL-17 in IMQ-treated skin lesion. Furthermore,
IMQ-induced skin inflammation and epidermal hyperplasia
were significantly decreased in Tcrd/ mice. In contrast to
IL-23-induced psoriasis-like model, IMQ-induced epidermal
hyperplasia was also significantly decreased in Tcra/ mice,
suggesting that both ab T cells and gd T cells contribute to
IMQ-induced skin pathology. However, IMQ-induced neutrophil
infiltration was significantly decreased only in Tcrd/ mice (not
in Tcra/mice), suggesting that dermal gd T cells are the major
IL-17-producing cells in skin. Furthermore, IL-22 mRNA was not
different amongWT, Tcra/, and Tcrd/mice. Thus, dermal gd
T cells also play a critical role in natural stimuli-induced psoriasis.
These data also suggest that the roles of IL-17, IL-22, gd T cells,
and ab T cells may vary in their degree of contribution to skin
pathology depending on whether IL-23 or IMQ is used to induce
skin inflammation.
In support of possible bacterial initiation of psoriasis, we did
find that pathogen products have a stimulatory effect on dermal
gd T cell IL-17 production. TLR and dectin-1 ligands promotedIL-17 production from dermal gd T cells in combination with
IL-23. The synergistic effect was dependent on the IL-1R sig-
naling pathway. CD44hiCCR6+ gd T cells express TLR1, TLR2,
and dectin-1 (Martin et al., 2009); thus, these pathogen products
may directly stimulate dermal gd T cells to produce IL-17. In
addition, pathogen products may stimulate IL-1b production
that synergizes with IL-23 to induce potent IL-17 production.
Although IL-23- or IMQ-induced psoriasis-like skin lesions in
mice share some clinical and histological characteristics with
human psoriasis (Chan et al., 2006), there are differences. Most
notably, human skin does not have DETCs whereas T cells
bearing abTCR exist predominantly in human dermis. Thus, the
importance of dermal gd T cells as the major IL-17-producing
T cells needs to be tested in human psoriasis patients. In healthy
controls, CD3+ T cells are scarce and are predominantly ab
T cells. gd T cells constitute only 5%–10% of total dermal leuko-
cytes. We found that gd T cells were significantly increased in
psoriatic skin consistent with a previous pathology report (Seung
et al., 2007). In addition, both percentage and absolute numbers
of IL-17-producing gd T cells were significantly more than those
ofgdTcells. The increasedgdTcell infiltration implies that these
cells may expand locally. Alternatively, these gd T cells may also
migrate from the periphery into the skin dermis via chemotaxis.
Local chemokineCCL20 production is also increased in psoriatic
skin (Kryczek et al., 2008). Although gd T cells are conventionally
considered to be innate immune cells that provide early and rapid
responses including high amounts of effector cytokines such as
IFN-g and IL-17 in the models of infection, tumor, and exposure
to injury (Gao et al., 2003; Hamada et al., 2008; Matsubara
et al., 2009), the increased frequency of dermal gd T cells in psori-
atic skin suggests that gd T cells are also crucial in the form of
chronic inflammation. This may be not very surprising because
marked expansion of gd T cells occurs in relatively late stages
of infection and chronic inflammation (Roark et al., 2007; Simo-
nian et al., 2006). Thus, dermal gd T cells may engage in immune
responses both early and late. Taken together, our results
emphasize the importance of dermal gd T cells on innate IL-17
production. Dermal gd T cells represent a major source of IL-17
that promotes the development and progression of skin inflam-
mation such as psoriasis.
EXPERIMENTAL PROCEDURES
Mice
WT, Tcrd/, Tcra/, and Il1r1/ mice on C57BL/6 background were
purchased from Jackson Laboratory. C57BL/6 Tcrd/ mice do not have
dermatitis (Girardi et al., 2002). Il17ra/mice have been previously described
(Ye et al., 2001). All animals were housed and treated in accordance with insti-
tutional guidelines and approved by the IACUC at the University of Louisville.
Human Subjects
Patients with psoriasis vulgaris were diagnosed based on the clinical and
histopathologic criteria. Skin biopsies were collected from the lesional site of
12 patients and 6 normal volunteers. All patients had not been treated on
systemic therapy for at least 4 weeks prior to the study entry. The study was
approved by the Shanghai Jiaotong University School of Medicine Research
Ethics Committee. All the participants gave their written informed consent.
Skin Cell Preparation and Stimulation
Mouse back skin or human skin was incubated in dispase to separate
epidermis and dermis. Epidermal cell suspensions were prepared byImmunity 35, 596–610, October 28, 2011 ª2011 Elsevier Inc. 607
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hyaluronidase, and DNase-I was used to obtain dermal cell suspensions.
Mouse cells were stimulated with varying concentrations of mouse rIL-23
(eBioscience), 100 ng/ml LPS, 1 mg/ml Pam3CSK4, 50 mg/ml Curdlan,
1 mg/ml Gardiquimod, or 0.5 mg/ml CpG for 2 days. The supernatants were
harvested for IL-17measurement by ELISA (Biolegend). Cells were also stimu-
latedwith IL-23 (50ng/ml) for 18hr in thepresence ofGolgiPlug (BDBioscience)
for intracellular IL-17 staining. In IL-1b blocking experiment, neutralizing IL-1b
mAb (2 mg/ml, eBioscience) or isotype mAb was added in the culture before
IL-23 stimulation. Additionally, skin DCs and Mf were purified from whole
skin cells by positive selectionwith anti-mouseCD11c andCD11bmicrobeads
(Miltenyi Biotec). Whole skin cells, skin cells devoid of DCs and Mf, or purified
skinDCsandMfwere stimulatedwith IMQ (2mg/ml) at different timepoints. For
human studies, dermal cells were stimulated with human rIL-23 (100 ng/ml) for
18 hr in the presence of GolgiPlug for intracellular IL-17 staining. To calculate
the absolute numbers of IL-17-producing cells, we used the following formula:
absolute IL-17-producing cell numbers = % of CD3+ cells 3% of gd+ or gd
T cells3%of IL-17-positive cells3 total cell numbers. To normalize the base-
lines for all samples, we used per million cells as baseline.
Flow Cytometry Analysis and Intracellular Staining
Mouse bTCR, CD3, and IL-17A mAbs were obtained from BD Biosciences.
Mouse gdTCR, RORgt, and CD27 and human gdTCR, CD3, and IL-17A
mAbs were purchased from eBioscience. Mouse CCR6, IL-22 mAbs were
obtained fromR&D system. All mouse TCR Vg antibodies were kindly provided
by R. O’Brien (National Jewish Health, Denver, CO). For intracellular staining,
cells were first stained with different cell surface Abs and then fixed, permea-
bilized, and stained intracellularly for IL-17, IL-22, TNF-a, IFN-g, or RORgt. The
relevant isotype control mAbs were also used. Samples were harvested with
a BD FACS Calibur and analyzed with FlowJo software (TreeStar).
Cell Sorting
The whole skin cell suspensions were stained with mouse CD3 and gdTCR
mAbs. Epidermal and dermal gd T cells were sorted by MoFlow high-speed
sorter. In addition, dermal cell suspensions were stained with mouse CD3
and gdTCR mAbs and dermal gd+ and gd T cells were sorted.
In Vivo Mouse Vg4 T Cell Depletion
Mouse Vg4 Ab (250 mg) or isotype control mAb was intravenously injected
into mice for 3 days. Mice were sacrificed and dermal cell suspensions were
stimulated with IL-23 for intracellular IL-17 staining.
Establishment of Psoriasis-like Mouse Models
IL-23-induced psoriasis-like mouse model was established as previously
described (Chan et al., 2006). In brief, IL-23 (1 mg) or vehicle control was daily
intradermally injected on the back skin of WT, Tcrd/, Tcra/, or Il17ra/
mice for 4 days. IMQ-induced psoriasis-like model was described previously
(van der Fits et al., 2009). Mice were treated with a daily topical dose of
commercially available IMQ cream (5%) (Aldara; 3M Pharmaceuticals) on the
shaved back for 3 or 5 consecutive days. Mice were sacrificed and the skin
samples were embedded and froze in OCT for H&E and immunohistochem-
istry (IHC) staining. In some experiments, skin DLNs and spleens were also
isolated for intracellular cytokine staining.
Skin Histology and IHC Staining
Skin sections were stained with H&E and the epidermal thickness was deter-
mined by measuring the average interfollicular distance under the microscope
in a blinded manner. For IHC staining, skin cryosections were fixed, blocked,
and then stained with rat-anti-mouse Gr-1 followed by goat-anti-rat IgG
secondary Ab (Southern Biotech). Slides were developed with 3-amino-9-eth-
ylcarbazole (AEC) substrate solution (Vector Laboratories) and then counter-
stained with hematoxylin. Images were acquired at 3200 magnification with
Aperio ScanScope digital scanners and Gr-1 expression was quantitatively
analyzed as mean intensity with Image-pro software (Media Cybernetics Inc.).
Immunofluorescence Staining
Human skin sampleswere fixed, cryosectioned, blocked, and then stainedwith
the following primary Abs: mouse anti-human gdTCR and CD3 (eBioscience),608 Immunity 35, 596–610, October 28, 2011 ª2011 Elsevier Inc.rabbit anti-human or mouse IL-23p19 (Abcam), and biotinylated mouse anti-
human CD11c (eBioscience) or CD68 (Biolegend). For mouse skin samples,
frozen sections were stained with primary Abs of rabbit anti-human or mouse
IL-23p19 (Abcam) and APC-hamster anti-mouse CD11c (eBioscience) or
APC-rat anti-mouse F4/80 (eBioscience). Images were acquired by Leica
TCS SP5 confocal microscope system.
RNA Extraction and Real-Time Quantitative PCR
RNAs were isolated with a QIAGEN RNeasy kit (QIAGEN). After reverse
transcription into cDNA with a Reverse Transcription Kit (Bio-Rad), qPCR
was then performed on MyiQ single color RT-PCR detection system with
SYBRGreen Supermix (Bio-Rad) and gene-specific primers were summarized
in Table S1. We normalized gene expression amount to b-2 microglobulin
(b-MG) housekeeping gene and represented data as fold differences by the
2DDCt method, where DCt = Cttarget gene  Ctb-MG and DDCt = DCtinduced 
DCtreference.
Statistical Analysis
All quantitative data are shown as mean ± SEM unless otherwise indicated.
All samples were compared with 2-tailed, unpaired Student’s t test or
a Mann-Whitney test as indicated. A p value less than 0.05 was considered
significant. Statistical analysis was performed with GraphPad Prism software.
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